ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nektar Therapeutics Investors to Secure Counsel Before Important Deadline in Securities Class Action - NKTR

Core Viewpoint - Rosen Law Firm is reminding investors who purchased Nektar Therapeutics securities between February 26, 2025, and December 15, 2025, of the May 5, 2026, deadline to become a lead plaintiff in a class action lawsuit [1]. Group 1: Class Action Details - Investors who bought Nektar securities during the specified class period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [1]. - A class action lawsuit has already been filed, and interested parties can join by submitting a form or contacting the law firm [2][5]. - The lawsuit alleges that defendants made false or misleading statements regarding the REZOLVE-AA trial, which could have negatively impacted its results and misled investors [4]. Group 2: Law Firm Credentials - Rosen Law Firm emphasizes the importance of selecting qualified legal counsel with a successful track record in securities class actions, highlighting its own achievements in this area [3]. - The firm has secured significant settlements for investors, including over $438 million in 2019, and has been recognized as a leader in the field of securities class action litigation [3].